Abstract
This study examines the response to dexamethasone–doxorubicin–vincristine (DAV) therapy, followed by conditioning regimen and autologous stem cells transplantation (ASCT) in patients with multiple myeloma in relation with the presence of polymorphisms in genes involved in drug metabolism ( GSTP1) and DNA synthesis ( TYMS). GSTP1 G313G genotype (OR = 5.49; 95% CI, 1.3–22.5, p = 0.02) and TYMS A227A genotype (OR = 3.41; 95% CI, 1.3–8.9, p = 0.01) resulted significantly associated with a poor response following chemotherapy and the risk increased for the combined genotype (OR = 13.54; 95% CI, 2.0–91.3, p = 0.01). TYMS T157T genotype was significantly associated with a poor response after ASCT (OR = 4.60; 95% CI, 1.2–16.9, p = 0.02). Pre-therapeutic individual determination of the GSTP1 and TYMS polymorphisms could help in choosing the most appropriate protocol.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
